The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma

International Urology and Nephrology

Volumn 39, Issue 4, 2007, Pages 1031-1037

  Erdemir, Fikret ^a,b   Ozcan, Faruk ^c   Kılıcaslan, Isin ^c   Parlaktas, Bekir S ^b   Uluocak, Nihat ^b   Gokce, Ozgur ^c  

^a School of Medicine ^*  (Turkey)

^b GAZIOSMANPASA UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bladder; E cadherin; Progression; Superficial; Urothelial carcinoma

Indexed keywords

PEROXIDASE; UVOMORULIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME; UROGENITAL TRACT CANCER;

EID: 36649024113     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-006-9159-5     Document Type: Article

References (28)

1. Syrigos KN, Harrington KJ, Pignatelli M (1999) Role of adhesion molecules in bladder cancer an important part of the jigsaw. Urology 53:428-434
2. Gunlusoy B, Degirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR (2005) Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin. Urol Int 75:107-113
3. Sozen S, Akbal C, Sokmensuer C, Ekici S, Ozen H (2002) Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). Urol Int 69:200-206
4. Durkan GC, Brotherick L, Mellon JK (1999) The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin. BJU Int 83:424-428
5. Otto T, Birchmeier W, Schmidt U (1994) Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54:3120-3123
6. Imao T, Koshida K, Endo Y (1999) Dominant role of E-cadherin in the progression of bladder cancer. J Urol 161:692-698
7. Sobin DH, Witteking Ch (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York
8. Angulo C, Lopez JI, Grignon DJ, Sanchez-Chapado M (1995) Muscularis mucosae differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 45:47-53
9. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumors. Tumors of the urinary system and genital organs. Pathology and Genetics. IARC Press, Lyon, pp 90-109
10. Holzbeierlein JM, Smith JA (1999) Management of superficial Ta/T1/T1S bladder cancer. Comprehensive textbook of genitourinary oncology. 2nd edn. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS ed, pp 384-394
11. Hasui Y, Osada Y, Kitada S (1994) Significance of invasion to the muscularis mucosaee on the progression of superficial bladder cancer. Urology 43:782-786
12. Holmang S, Hedelin H, Anderstrom C (1997) The importance of the depth of invasion in stage T1 bladder carcinoma: A prospective cohort study. J Urol 157:800-804
13. Dixon JS, Gosling JA (1983) Histology and fine structure of the muscularis mucosae of the human urinary bladder. J Anat 136:265-271
14. Raghaven D, Shipley WU, Garnick MB (1990) Biology and management of bladder cancer. N Engl J Med 322:1129-1138
15. Esrig D, Spruck CH, Nichols PW (1993) P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397
16. Shimazui T, Schalken JA, Giroldi LA (1996) Prognostic value of cadherin-associated molecules (α, β,and γ-catenins and p120cas) in bladder tumors. Cancer Res 56:4154-4158
17. Ross JS, Rosario AD, Figge HL (1995) E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol 26:940-944
18. Popov Z, Medina SGD, Belda MAL (2000) Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 83:209-214
19. Bringuier PP, Umbas R, Schaafsma HE (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53:3241-3245
20. Kinsella AR, Green B, Lepts GC (1993) The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis. Br J Cancer 67:904-949
21. Matsuura K, Kawanishi J, Fuji S (1992) Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid. Br J Cancer 66:1122-1130
22. Umbas R, Isaacs WB, Bringuier PP (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933
23. Rebel JMJ, Thijsenn CDEM, Vermey M (1994) E-cadherin expression determines the mode of replacement of normal urothelium by human bladder carcinoma cells. Cancer Res 54:5488-5492
24. Nakopoulou L, Zervas A, Gakiopoulou H (2000) Prognostic value of E-cadherin, β-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 20:4571-4578
25. Otto T, Bex A, Schmidt U (1997) Improved prognosis assessment for patients with bladder carcinoma. J Pathol 150:1919-1923
26. Sun W, Herrera GA (2004) E-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol 8:17-22
27. Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA Jr, Wheeler TM, Lerner SP (2001) E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 165:1473-1479
28. Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F, Witjes JA (1998) Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 52:1009-1014